{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:20:21Z","timestamp":1793881221316,"version":"4.7.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ekir.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T08:19:05Z","timestamp":1730276345000},"page":"40-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation"],"prefix":"10.1016","volume":"10","author":[{"given":"Nicholas W.","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.10.016_bib1","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.016_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof","year":"2016","journal-title":"Eur J Cardio Thorac Surg"},{"key":"10.1016\/j.ekir.2024.10.016_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ekir.2024.10.016_bib4","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2024.10.016_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ekir.2024.10.016_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib9","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2024.10.016_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and Rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.016_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2024.10.016_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2024.10.016_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2024.10.016_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2024.10.016_bib15","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.016_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of Rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2024.10.016_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of Rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.10.016_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose Rivaroxaban in chronic hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2024.10.016_bib19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2024.10.016_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9511499","article-title":"To measure or not to measure: direct oral anticoagulant laboratory assay monitoring in clinical practice","volume":"2023","author":"Ahuja","year":"2023","journal-title":"Adv Hematol"},{"key":"10.1016\/j.ekir.2024.10.016_bib21","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2024.10.016_bib22","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/TP.0000000000004195","article-title":"A\u00a0review of direct-acting oral anticoagulants and their use in solid organ transplantation","volume":"106","author":"Rimsans","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.10.016_bib23","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.016_bib24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.016_bib25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with Apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.016_bib26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J\u00a0Hosp Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.14021021","article-title":"Apixaban versus warfarin for Treatment of venous thromboembolism in Patients Receiving Long-Term Dialysis","volume":"17","author":"Wetmore","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.016_bib28","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and Safety of Apixaban versus warfarin in venous thromboembolism Patients with Chronic Kidney Disease","volume":"122","author":"Cohen","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.016_bib29","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/bloodadvances.2019000972","article-title":"Outcomes associated with apixaban vs warfarin in patients with renal dysfunction","volume":"4","author":"Hanni","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2024.10.016_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.016_bib31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the Safety and Effectiveness of Apixaban versus warfarin in Patients with Severe Renal Impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ekir.2024.10.016_bib32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1060028019897053","article-title":"Characterizing the safety profile of Apixaban versus warfarin in moderate to severe chronic kidney disease at a Veterans Affairs hospital","volume":"54","author":"Herndon","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2024.10.016_bib33","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of Apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2024.10.016_bib34","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with Rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2024.10.016_bib35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and Efficacy of vitamin K antagonists versus Rivaroxaban in hemodialysis Patients with atrial fibrillation: a Multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.016_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter randomized controlled trial of vitamin K antagonist replacement by Rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study","volume":"31","author":"De Vriese","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.016_bib37","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib38","article-title":"Effectiveness and safety of\u00a0Rivaroxaban versus warfarin in Taiwanese patients with\u00a0end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study","volume":"16","author":"Lin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.10.016_bib39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ejh.13383","article-title":"Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis","volume":"104","author":"Miao","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ekir.2024.10.016_bib40","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US renal data system 2020 annual data report: epidemiology of kidney disease in the United States","volume":"04","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.10.016_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00003088-199631040-00005","article-title":"Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis","volume":"31","author":"Taylor","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2024.10.016_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100646","article-title":"Pharmacokinetics of Apixaban among peritoneal dialysis patients","volume":"5","author":"Fung","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib43","first-page":"147","article-title":"Safety and efficacy of Apixaban use in peritoneal dialysis: a review of the literature","volume":"37","author":"Amani","year":"2021","journal-title":"J\u00a0Pharm Technol"},{"key":"10.1016\/j.ekir.2024.10.016_bib44","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2024.10.016_bib45","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1097\/CCM.0b013e318187815a","article-title":"End-stage renal disease patients on renal replacement therapy in the intensive care unit: short- and long-term outcome","volume":"36","author":"Bell","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib46","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.chest.2019.05.025","article-title":"Direct-acting oral anticoagulants in critically ill patients","volume":"156","author":"Rali","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.ekir.2024.10.016_bib47","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/10600280211046087","article-title":"Apixaban and Rivaroxaban anti-Xa level monitoring versus standard monitoring in hospitalized patients with acute kidney injury","volume":"56","author":"Towers","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2024.10.016_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12882-021-02248-7","article-title":"Pharmacokinetics and dialytic clearance of apixaban during in\u00a0vitro continuous renal replacement therapy","volume":"22","author":"Andrews","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2024.10.016_bib49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC Expert Consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology clinical expert consensus document task force","volume":"69","author":"Doherty","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2024.10.016_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12873","article-title":"Direct oral anticoagulant considerations in solid organ transplantation: a review","author":"Salerno","year":"2017","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib51","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"Update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.016_bib52","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13853","article-title":"Utilization of direct-acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices","volume":"34","author":"Lichvar","year":"2020","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14897","article-title":"Descriptive analysis evaluating the use of direct oral anticoagulation therapy in heart and lung transplant recipients","volume":"37","author":"Rubido","year":"2023","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib55","article-title":"Deceased donor renal transplantation in patients on apixaban at time of transplant surgery: a case series","volume":"01","author":"Lange","year":"2021","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib56","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/lt.26521","article-title":"Deceased donor liver transplantation in patients on direct oral anticoagulants at the time of transplant surgery: A case series","volume":"28","author":"Salerno","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2021.02.022","article-title":"Venous thromboembolism in solid-organ transplant recipients: findings from the RIETE registry","volume":"201","author":"Garc\u00eda-Ortega","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.ekir.2024.10.016_bib58","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1016\/j.transproceed.2020.02.171","article-title":"Incidence of direct oral anticoagulant prescriptions in kidney transplant recipients in Ontario, Canada","volume":"52","author":"Somaili","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2024.10.016_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/phar.2485","article-title":"Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review","volume":"41","author":"Bixby","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ekir.2024.10.016_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5500\/wjt.v9.i6.134","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation","volume":"9","author":"Bukhari","year":"2019","journal-title":"World J Transplant"},{"key":"10.1016\/j.ekir.2024.10.016_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14474","article-title":"Can direct oral anticoagulants be used in kidney transplant recipients?","volume":"35","author":"Parker","year":"2021","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib62","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/tri.13599","article-title":"Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study","volume":"33","author":"Bixby","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2024.10.016_bib63","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/TP.0000000000003168","article-title":"Efficacy and safety of direct oral anticoagulants in kidney transplantation: a single-center pilot experience","volume":"104","author":"Leon","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.10.016_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285412","article-title":"Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients","volume":"18","author":"Firth","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.10.016_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2023.08.003","article-title":"Immunosuppressive therapy and oral anticoagulation in kidney transplant recipients: direct oral anticoagulants versus vitamin-K antagonists","volume":"119","author":"Santoro","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ekir.2024.10.016_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0000000000000356","article-title":"Effect of the direct oral anticoagulants Rivaroxaban and Apixaban on the disposition of calcineurin inhibitors in transplant recipients","volume":"39","author":"Vanhove","year":"2017","journal-title":"Ther Drug Monit 02"},{"key":"10.1016\/j.ekir.2024.10.016_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14396","article-title":"Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients","volume":"35","author":"Salerno","year":"2021","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/tri.13804","article-title":"Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation","volume":"34","author":"Pfrepper","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2024.10.016_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14513","article-title":"Safety of direct oral anticoagulants in solid organ transplant recipients: A meta-analysis","volume":"36","author":"Zakko","year":"2022","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.10.016_bib70","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/TP.0000000000000223","article-title":"Increased levels of Rivaroxaban in patients after liver transplantation treated with cyclosporine A","volume":"98","author":"Wannhoff","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.10.016_bib71","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.13934","article-title":"Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of Rivaroxaban in healthy volunteers","volume":"85","author":"Brings","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2024.10.016_bib72","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/cts.12580","article-title":"Drug-drug interaction study of Apixaban with cyclosporine and tacrolimus in healthy volunteers","volume":"11","author":"Bashir","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ekir.2024.10.016_bib73","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K Oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2024.10.016_bib74","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/15269248211024601","article-title":"The impact of Rivaroxaban and Apixaban on tacrolimus trough levels","volume":"31","author":"Scheibner","year":"2021","journal-title":"Prog Transplant"},{"key":"10.1016\/j.ekir.2024.10.016_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2020.106682","article-title":"Absence of interaction between Rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation","volume":"130","author":"Camporese","year":"2020","journal-title":"Vascul Pharmacol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492401982X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492401982X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T09:12:17Z","timestamp":1734945137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492401982X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S246802492401982X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.10.016","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}